NIBIB Biomedical Technology Resource Centers (BTRC’s) (P41) – This FOA issued by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), NIH, encourages grant applications for BTRC’s that are funded using the P41 mechanism. BTRC’s conduct research and development on new technologies that are driven by the needs of basic, translational, and clinical researchers. BTRCs may be developed in a specific, narrow technological area, or they may utilize an integrated approach to the development of tools and methods across a broader line of inquiry. In either case, a BTRC assembles a critical mass of both technological and intellectual resources with the intent of exploiting advances in instrumentation and methodology for biomedical research. This intense synergy between technology development and biomedical problem solving defines the BTCR’s as fundamentally different in character from laboratories engaged in investigator-initiated research that may have more narrowly defined goals. A BTRC also must provide Service and Training to outside investigators and must disseminate the technology and methods it has developed. These efforts require the commitment of far greater financial and personnel resources to non-science activities than is expected for other types of research efforts. The goal of these efforts is to export the technology and expertise of the BTRC into the broader community, achieving a wider impact on biomedical research than would be possible through the projects in which the BTCR can participate directly. Industrial partnerships are not required, but they are welcome when appropriate. Eligibility: All. LOI Due Date: 30 days prior to full proposal deadline. Full Proposal Due Dates: May 25, September 25, January 25 annually through May 8, 2013.
Posted Date: March 25, 2010
Program Announcement (PA) Number: PAR-10-153
————————————————————————————–
Diet Composition and Energy Balance (R01) – The goal of this funding opportunity announcement (FOA) is to invite Research Project Grant (R01) applications investigating the role of diet composition in energy balance, including studies in both animals and humans. Both short and longer-term studies are encouraged, ranging from basic studies investigating the impact of micro-or macronutrient composition on appetite, metabolism, and energy expenditure through clinical studies evaluating the efficacy of diets differing in micro- or macronutrient composition, absorption, dietary variety, or energy density for weight loss or weight maintenance. Collaborations between basic and clinical researchers, which explore mechanisms underlying differences in response to diet composition, are particularly encouraged. Eligibility: All. Opening Date: May 5, 2010. Closing Date: June 5, October 5, and February 5 annually through May 8, 2013.
Posted Date: March 24, 2010
Funding Opportunity Number: PA-10-152
————————————————————————————–
Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21) – The purpose of this FOA is to support innovative exploratory/developmental investigations in primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models, including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for, primary immunodeficiency diseases. Investigators who have no prior history of receiving independent NIH funding or no prior history of receiving independent NIH funding in this field are encouraged to apply to this FOA. This FOA will use the NIH Exploratory/Developmental (R21) award mechanism and runs in parallel with a FOA of identical scientific scope, PA-10-147, that encourages applications under the R03 small grant mechanism. Total Funding: $650,000; Award Ceiling: $200K. Eligibility: All. Opening Date: May 16, 2010. Submission Due Dates: June 16, October 16, February 16, annually until May 8, 2013.
Posted Date: March 22, 2010
Program Announcement (PA) Number: PAS-10-148
————————————————————————————–
Small Grants on Primary Immunodeficiency Diseases (R03) – The purpose of this Funding Opportunity Announcement (FOA) is to support small grants in primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models, including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for primary immunodeficiency diseases. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources. Investigators who have no prior history of receiving independent NIH funding or no prior history of receiving independent NIH funding in primary immunodeficiency diseases research, are encouraged to apply to this FOA. This FOA will utilize the NIH Small Research Grant (R03) award mechanism and runs in parallel with an FOA of identical scientific scope, PAS-10-148, that encourages applications under the R21grant mechanism. Total Funding: $150K. Eligibility: All. Opening Date: May 16, 2010. Submission Due Dates: June 16, October 16, February 16, annually until May 8, 2013.
Posted Date: March 22, 2010
Program Announcement (PA) Number: PA-10-147
————————————————————————————–
Grants for Alzheimer’s Disease Drug Discovery (R21) – The goal of this FOA is to advance the discovery of new, efficacious therapies for the treatment, delay of progression, or prevention of Alzheimer’s disease (AD), mild cognitive impairment (MCI) and age-related cognitive decline. This FOA encourages the early stages of drug discovery necessary to identify promising disease-modifying therapies as well as treatments aimed at ameliorating the cognitive and neuropsychiatric/behavioral symptoms characteristic of Alzheimer’s disease. Studies aimed at the discovery and testing of therapies directed at a variety of established as well as novel therapeutic targets are encouraged. The goal is not to duplicate or compete with pharmaceutical companies but to encourage the process of discovering new, innovative, and effective therapeutics for the prevention and treatment of the cognitive impairment and behavioral symptoms associated with Alzheimer’s disease. Eligibility: All. Opening Date: May 16, 2010. Submission Due Dates: June 16, October 16, February 16, annually until May 8, 2013.
Posted Date: March 22, 2010
Program Announcement (PA) Number: PAS-10-151
————————————————————————————–
NINDS Exploratory/Developmental Projects in Translational Research for Resistant Epilepsy and Epileptogenesis (R21) – This FOA, from the National Institute of Neurological Disorders and Stroke (NINDS) encourages applications for projects intended to complete preliminary steps in the pipeline for the preclinical development of therapeutics to cure epilepsy, prevent the emergence of epilepsy following brain injury (including status epilepticus, traumatic brain injury, stroke, encephalitis, or other injury) or in other high-risk groups, or to better treat individuals with intractable epilepsy. Such projects, if successful, should lead directly to a subsequent project that will include all remaining activities for submission of an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application to the Food and Drug Administration (FDA). Only Aims required for therapy development can be supported in this program. This program excludes clinical research, basic research, and studies of disease mechanisms. This FOA will use the NIH Exploratory/Developmental (R21) award mechanism and runs in parallel with a FOA of identical scientific scope, PAR-10-144, that encourages applications under the Cooperative Agreement (U01) mechanism. Total Funding: $900K. Eligibility: All. Opening Date: May 16, 2010. Submission Due Dates: June 16, October 16, February 16, annually until May 8, 2013.
Posted Date: March 19, 2010
Program Announcement (PA) Number: PAR-10-143
————————————————————————————–
NINDS Cooperative Program in Translational Research for Resistant Epilepsy and Epileptogenesis (U01) – The goal of this FOA, from the National Institute of Neurological Disorders and Stroke (NINDS) is to support preclinical development of new therapies to cure epilepsy, prevent the emergence of epilepsy following brain injury (including status epilepticus, traumatic brain injury, stroke, encephalitis, or other injury) or in other high-risk groups, or to better treat individuals with intractable epilepsy. The program will facilitate solicitation, development, and review of therapy-directed projects to accelerate the translation of basic research discoveries into therapeutic candidates for clinical testing. This program is specifically directed at projects that include therapeutic leads with demonstrated activity against the intended disease target. The program supports preclinical optimization and testing of these leads and projects must be sufficiently advanced that an IND or IDE application to the FDA can be submitted by the end of the project period. This FOA will utilize the U01 Cooperative Agreement mechanism and runs in parallel with a FOA of identical scientific scope, PAR-10-143, that encourages applications under the NIH Exploratory/Developmental (R21) mechanism. Total Funding: $3.6M. Eligibility: All. LOI Due Date: 30 days prior to each submission date. Submission Due Date: June 5, October 5, February 5 annually until May 2013.
Posted Date: March 19, 2010
Funding Opportunity Number: PAR-10-144
————————————————————————————–
Development and Translation of Medical Technologies that Reduce Health Disparities (SBIR [R43/R44]) – This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop and translate medical technologies aimed at reducing disparities in healthcare access and health outcomes. Appropriate medical technologies should be effective, affordable, culturally acceptable, and deliverable to those who need them. Responsive grant applications must involve a formal collaboration with a healthcare provider or other healthcare organization serving a health disparity population. Applications submitted to this funding opportunity must address one or more of these barriers in developing technologies that will impact health disparities: 1) Physical Barriers; 2) Knowledge Barriers; 3) Infrastructure Barriers; 4) Economic Barriers; 5) Cultural Barriers. Total Funding: $3.45M. Eligibility: US Small Businesses. Opening Date: April 20, 2010. LOI Due Date: April 20, 2010, August 22, 2010. Application Due Date: May 20, 2010, September 22, 2010.
Posted Date: March 19, 2010
Request For Applications (RFA) Number: RFA-EB-10-002
————————————————————————————–
NCMHD Building Research Infrastructure and Capacity (P20) – This FOA issued by the National Center on Minority Health and Health Disparities (NCMHD) encourages grant applications from non-research intensive institutions that propose to build, strengthen and/or enhance the research infrastructure and research training capacity of their institution. Each NCMHD Building Research Infrastructure and Capacity (BRIC) grant application must have a plan to establish a research capacity-building infrastructure program. This plan must include benchmarks, for training students and developing a cadre of clinical, biomedical and behavioral research junior scientists who possess the skills, knowledge and abilities to engage in leading edge research that ultimately will contribute to reducing and eliminating health disparities in the United States. Total Funding: $5M. Eligibility: Universities and Colleges.
Posted Date: March 19, 2010
Funding Opportunity Number: RFA-MD-10-002
————————————————————————————–
New Biomedical Frontiers at the Interface of the Life and Physical Sciences (R01) – The goal of this funding opportunity announcement, issued by the National Institutes of Health and the National Science Foundation, is to encourage grant applications from institutions/organizations that propose discovery research that may create entirely new areas of biomedical investigation through bridging the physical and life/behavioral sciences. Appropriate topics include, but are not limited to: 1) self-healing/replicating nanodevices; 2) biological computing; 3) biologically-inspired next generation materials biological power sources; 4) non-invasive identification of disease modeling and real-time observation of biomolecular and pharmacologic interactions: in vivo, in vitro, in silico; 5) theoretical models of intercellular processes and robust methods for manipulation; 6) accurate prediction of electrostatic interactions, solvent effects in aqueous biological systems, and trajectories of reactions; 7) adapt complex methodologies, such as dynamical systems analysis, agent based modeling, discrete event simulation, and network analysis to problems such as quorum sensing, interconnected networks of cellular regulatory pathways, signal transduction, and social interactions and behavior change. The purpose of this initiative is to provide support for cutting-edge, visionary research, only possible through bridging the sciences, with the goal of setting the stage for the next biomedical breakthrough. Eligibility: All. Opening Date: April 18, 2010. LOI Due Dates: April 18, 2010; April 18, 2011; April 18, 2012. Application Due Dates: May 18, 2010; May 18, 2011; May 18, 2012
Posted Date: March 18, 2010
Program Announcement (PA) Number: PAR-10-142
————————————————————————————–
Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA) In the Epilepsies (R01) – This FOA solicits Research Project Grant (R01) applications from institutions/organizations proposing exceptionally innovative research on novel hypotheses or difficult problems, solutions to which would have an extremely high impact on biomedical or bio-behavioral research in the epilepsies. To encourage exceptionally innovative epilepsy research, this FOA solicits applications from investigators who want to test novel, unconventional hypotheses or pursue major methodological or technical challenges. The potential impact of the proposed research on the epilepsy community must be substantial. The investigator should anticipate starting and completing the project during the term of the award, since this FOA is not for support of ongoing research or for pilot projects, and awards are not renewable. Total Funding: $2M. Eligibility: All. Opening Date: July 13, 2010. LOI Due Date: July 13, 2010. Closing Date: August 13, 2010.
Posted Date: March 18, 2010
Request for Applications (RFA) Number: RFA-NS-11-003
————————————————————————————–
Ancillary Studies in Immunomodulation Clinical Trials (R01) – This FOA invites R01 applications for mechanistic studies in clinical trials of: (1) immunomodulatory interventions for immune system mediated diseases, including, but not limited to: asthma and allergic diseases; graft rejection in solid organ, cell, and tissue transplantation; graft versus host disease in hematopoietic stem cell transplantation; and chronic inflammatory, autoimmune, and immunodeficiency diseases; and (2) preventative and therapeutic, vaccines for non-HIV/AIDS infectious diseases. The goal of this FOA is the inclusion of subjects and utilization of subject samples from clinical trials for the evaluation of immunologic and other relevant parameters in order to study and define the underlying immunological mechanisms of the intervention or vaccine, the mechanisms of disease pathogenesis, biomarkers of disease activity and therapeutic effect, and mechanisms of human immunologic function. This FOA is a renewal with modifications of RFA AI-08-011 (http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-08-011.html). Total Funding: $2M. Eligibility: All. Opening Date: April 9, 2010. LOI Due Date: April 9, 2010. Closing Date: June 9, 2010.
Posted Date: March 18, 2010
Request for Applications (RFA) Number: RFA-AI-10-014
————————————————————————————–
Team-Based Design in Biomedical Engineering Education (R25) – This FOA, issued by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) and the Eunice K. Shriver National Institute of Child Health and Human Development (NICHD), encourages applications from institutions that propose to establish new or to enhance existing team-based design courses in undergraduate Biomedical Engineering departments or programs. This FOA targets undergraduate students at the senior level but may also include junior undergraduates and first-year graduate students. Courses that address innovative and/or groundbreaking development, multidisciplinary/ interdisciplinary training, and diversity recruitment are especially encouraged. Eligibility: Universities and Colleges. Opening Date: April 18, 2010. LOI Due Dates: April 19, 2010; April 18, 2011; April 18, 2012. Application Due Dates: May 18, 2010; May 18, 2011; May 18, 2012.
Posted Date: March 18, 2010
Program Announcement (PA) Number: PAR-10-140
————————————————————————————–
Transforming Biomedicine at the Interface of the Life and Physical Sciences (R01) – The NIH and the NSF are issuing this joint announcement to encourage grant applications from institutions/organizations to encourage quantitative/physical scientists and engineers to apply their unique skills and perspectives to overcome important problems in translational research and catalyze clinical advances. The goal of this funding opportunity announcement is to stimulate quantitative and physical scientists to work with biomedical scientists to transform technological innovation and basic knowledge in the quantitative sciences into new or improved devices or systems for health care. Projects must propose an innovative application of the physical or quantitative sciences to help solve a translational or clinical problem. The application must highlight why a bridging approach is necessary and how this will lead to clinical implementation. Eligibility: All. Opening Date: April 18, 2010. LOI Due Dates: April 18, 2010; April 18, 2011; April 18, 2012. Application Due Dates: May 18, 2010; May 18, 2011; May 18, 2012.
Posted Date: March 18, 2010
Program Announcement (PA) Number: PAR-10-141
————————————————————————————–
Non-Human Primate Core Humoral Immunology Laboratory for AIDS Vaccine Research and Development – The purpose of the proposed contract will be to provide a Nonhuman Primate Core Humoral Immunology Laboratory that will conduct humoral immunology assays in support of studies that evaluate prototype AIDS vaccines. The objective of the Core Laboratories has been to insure standardization and comparability of the assays conducted for preclinical NHP studies and to provide a common basis for assessment of the immunogenicity and efficacy of candidate HIV and SIV vaccines. The contract will support the development, conduct, and improvement of assays designed to evaluate and characterize the humoral immune responses of nonhuman primates that have been immunized with candidate HIV or SIV vaccines or infected with SIV, SHIV, or HIV in studies conducted at the NIAID Simian Vaccine Evaluation Unit (SVEU) contract sites or by NIH-supported investigators. Eligibility: All. Closing Date: June 17, 2010.
Posted Date: March 17, 2010
Solicitation Number: RFP_NIAID-DAIDS-NIHAI2009072
————————————————————————————–
ARRA – Comprehensive Biospecimen Resource – SAIC-Frederick (SAIC-F), on behalf of the National Cancer Institute (NCI), announces its intent to publish, in Spring 2010, a solicitation for a Comprehensive Biospecimen Resource (CBR) that will serve as the essential infrastructure for centralized processing, quality control, molecular validation, storage and distribution of high-quality biospecimens. Under its Prime Contract with the NCI, SAIC-F will issue this solicitation as part of the NCI Office of Biorepositories and Biospecimen Research (OBBR) initiative in support of the cancer Human Biobank (caHUB) under the American Recovery and Reinvestment Act (ARRA). This type of infrastructure will include the multi-disciplinary program essential to the caHUB vision to provide high quality tissue for the cancer research and development enterprise. caHUB is a new initiative being developed by the NCI Office of Biorepositories and Biospecimen Research. Through an advanced network of tissue acquisition, biorepository operations, pathology review, and bioinformatics capabilities, caHUB will develop the high quality, clinically annotated biospecimens that are essential resources to accelerate the development of molecular-based diagnostics and therapeutics for personalized medicine.
Posted Date: March 18, 2010
Solicitation Number: ST10-1035
————————————————————————————–
Diabetes Risk Across Women’s Lifespan – The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks to acquire valid and reliable data from a cohort of women with a history of gestational diabetes to: 1) Investigate the role of genetic variants important for glucose homeostasis in the progression of gestational diabetes to type 2 diabetes; 2)To quantify the role of selected environmental factors in the progression of gestational diabetes to type 2 diabetes; 3)To assess the interactions of genetic and environmental factors in the progression of gestational diabetes to type 2 diabetes; and 4)To identify biochemical markers for type 2 diabetes and for subsequent use in predicting the development of type 2 diabetes among women with a history of gestational diabetes. A secondary goal of this study is to obtain baseline data on the children born from a pregnancy complicated by GDM and evaluate the feasibility of studying their long-term health conditions, possibly by establishing a new cohort comprising offspring. RFP-NIH-NICHD-DESPR-10-06 will be available electronically within 10 days from this notification. Response Due Date: May 13, 2010.
Posted Date: March 18, 2010
Solicitation Number: NIH-NICHD-DESPR-10-06
————————————————————————————–
Preclinical Pharmacokinetic and Pharmacological Studies of Anticancer and Other Therapeutic Agents – The mission of the Developmental Therapeutics Program (DTP), DCTD, NCI centers on the discovery and preclinical development of agents with clinical anticancer potential. Characterization of the pharmacokinetics of new compounds provides important information for the selection of optimal drug development candidates and for the design and interpretation of preclinical efficacy studies, including the selection of formulations, routes, and schedules of administration. Moreover, one objective of preclinical toxicology evaluations is the correlation of toxic effects of a compound with plasma concentrations and/or area under the curve (AUC). The successful outcome of these studies thus depends heavily on the availability of sensitive methods for quantifying compounds in biological fluids and the careful integration of preclinical pharmacology and toxicology data. Activities of any contract awarded from the proposed solicitation will include, but not be limited to, the following tasks: (1) Development of sensitive analytical methods to quantify compounds in plasma, urine, tissues, and other biological matrices; (2) Plasma stability and protein binding studies, which are conducted at an early stage of compound development to ensure proper sample handling and to aid in the interpretation of in vivo studies; (3) Pharmacokinetic evaluation of test compounds following administration to animals by various routes and schedules, including a determination of bioavailability by various routes; (4) Quantification and identification of drug metabolites generated in vivo and in various in vitro systems (S9 fractions. The offeror must possess a valid Nuclear Regulatory Commission (NRC) license. The offeror may not be a pharmaceutical, chemical, or biotechnology firm. The solicitation is scheduled for release on or about April 30, 2010.
Posted Date: March 18, 2010
Solicitation Number: N01-CM-07014-39
————————————————————————————–
Ancillary Studies in Clinical Trials (R01) – The purpose of this FOA is to solicit research grant applications to conduct time-sensitive ancillary studies related to heart, lung, and blood diseases and sleep disorders in conjunction with ongoing clinical trials and other large clinical studies supported by NIH or non-NIH entities. The program establishes an accelerated review/award process to support the crucial time frame in which these ancillary studies must be performed. Time-sensitive ancillary studies include those that require active longitudinal data collection and thus need to begin recruiting subjects as close as possible to the start of the parent study. The ancillary study can address any research questions related to the mission of NHLBI for which the parent study can provide participants, infrastructure, and data. The parent studies most often will be a clinical trial, but also can be an observational study or registry that can provide a sufficient cohort of well-characterized patients. Each ancillary study application must demonstrate the time-sensitive nature of the proposal and must explicitly address why an expedited review is essential to its feasibility. Total Funding: $4.8M. Number of Awards: 12. Eligibility: All. Opening Date: April 28, 2010. LOI Due Dates: April 28, 2010; August 30, 2010; December 28, 2010. Application Due Dates: May 28, 2010; September 30, 2010; January 28, 2011.
Posted Date: March 17, 2010
Request for Applications (RFA) Number: RFA-HL-10-024
————————————————————————————–
The Role of Cellular Organelles in Alcohol-Induced Tissue Injury (R01) – This FOA issued by the National Institute on Alcohol Abuse and Alcoholism, NIH, encourages applications that propose to study biological processes involving the cellular organelles in alcohol-induced tissue injury. Excessive alcohol consumption can damage many organ systems including the liver, heart, pancreas, brain, and lung. However, the mechanisms for these injuries are currently not fully understood. Cellular organelles play an important role in cellular functions and are significantly involved in alcohol-induced tissue injury. Thus, studies of alcohol’s effects on the structure and function of cellular organelles are critical to better understand the mechanisms of alcohol-induced injuries and to develop new strategies for their diagnosis and treatment. The purpose of this FOA is to: (1) better understand how acute or chronic alcohol consumption affects the structure and function of cellular organelles, and in turn, how these changes contribute to alcohol-induced injury; (2) investigate how variations of proteins in cellular organelles, or their regulation and function, including cellular signaling pathways, contribute to an individual’s response to acute or chronic alcohol intake and alcohol-induced tissue injury; (3) develop potential biomarkers for prognosis and diagnosis of tissue injury, or identify new targets for therapeutic interventions. This FOA aims to foster the utilization of innovative experimental design and emerging technologies, such as genomics, proteomics, metabolomics, bioinformatics, as well as novel microscopic imaging techniques that illuminate functions in intact cells and tissues, to generate new mechanistic and clinical insights into alcohol-induced tissue injuries. Eligibility: All. Opening Date: May 5, 2010. Application Due Dates: February 5, June 5, October 5 annually through May 2013.
Posted Date: March 17, 2010
Program Announcement (PA) Number: PA-10-085
————————————————————————————–
The Role of Cellular Organelles in Alcohol-Induced Tissue Injury (R21) – This FOA issued by the National Institute on Alcohol Abuse and Alcoholism, NIH, encourages applications that propose to study biological processes involving the cellular organelles in alcohol-induced tissue injury. Excessive alcohol consumption can damage many organ systems including the liver, heart, pancreas, brain, and lung. However, the mechanisms for these injuries are currently not fully understood. Cellular organelles play an important role in cellular functions and are significantly involved in alcohol-induced tissue injury. Thus, studies of alcohol’s effects on the structure and function of cellular organelles are critical to better understand the mechanisms of alcohol-induced injuries and to develop new strategies for their diagnosis and treatment. The purpose of this FOA is to: (1) better understand how acute or chronic alcohol consumption affects the structure and function of cellular organelles, and in turn, how these changes contribute to alcohol-induced injury; (2) investigate how variations of proteins in cellular organelles, or their regulation and function, including cellular signaling pathways, contribute to an individual’s response to acute or chronic alcohol intake and alcohol-induced tissue injury; (3) develop potential biomarkers for prognosis and diagnosis of tissue injury, or identify new targets for therapeutic interventions. This FOA aims to foster the utilization of innovative experimental design and emerging technologies, such as genomics, proteomics, metabolomics, bioinformatics, as well as novel microscopic imaging techniques that illuminate functions in intact cells and tissues, to generate new mechanistic and clinical insights into alcohol-induced tissue injuries. Eligibility: All. Opening Date: May 16, 2010. Application Due Dates: February 16, June 16, October 16 annually through May 2013.
Posted Date: March 17, 2010
Program Announcement (PA) Number: PA-10-086
————————————————————————————–
Exploratory Cancer Prevention Studies Involving Molecular Targets for Bioactive Food Components (R21) – This FOA issued by the National Cancer Institute (NCI), NIH, encourages exploratory research on the role of nutrition in cancer prevention. Specifically, this FOA seeks to promote cancer prevention research to identify and characterize molecular targets for bioactive food components. The goal of this funding opportunity is to stimulate nutrition research using an exploratory and/or developmental (R21) approach to identify and characterize molecular targets for cancer prevention. Applications submitted in response to this FOA must consider the physiologically effective dietary exposure, both quantity and duration, needed to bring about a change in a relevant molecular target. Since the effectiveness of the bioactive food component may depend on the expression of target genes, the use of a variety of experimental models is appropriate. Applications must relate the response in a molecular target to an early morphologic change, such as in colon the formation of preneoplastic aberrant crypt foci (ACF), in breast ductal carcinoma in situ (DCIS), or in prostate intraepithelial neoplasia (PIN), etc. For the purpose of this FOA, a bioactive food component is defined as a dietary constituent that has a health benefit by altering one or more cellular processes when provided in quantities over and beyond that needed for basic nutrition. Eligibility: All. Opening Date: May 16, 2010. Application Due Dates: February 16, June 16, October 16 annually through May 2013.
Posted Date: March 17, 2010
Program Announcement (PA) Number: PA-10-088
————————————————————————————–
Stress Pathways in Alcohol Induced Organ Injury and Protection (R21) – This FOA issued by the National Institute on Alcohol Abuse and Alcoholism, NIH, encourages applications that propose studying the role of cellular stress responses, the cytoplasmic classical stress response or heat shock response (HSR) and the endoplasmic reticulum (ER) stress, in alcohol-induced tissue injury and tissue protection. While excessive alcohol use causes organ damage, moderate alcohol consumption may be beneficial. The underlying molecular mechanisms for this apparent dichotomy of alcohol’s harmful and salutary effects are currently not fully understood. Studies of the effects of alcohol on cellular stress pathways are critical to understand the mechanisms of alcohol-induced injuries or protection to develop new strategies for prevention, diagnosis and treatment. The purpose of this FOA is to: (1) acquire insight into how acute or chronic alcohol consumption affects cellular stress pathways and in turn, how these changes contribute to alcohol-induced injury/protection; (2) investigate how alcohol induced stress responses mediate cell survival and death signaling pathways at macromolecular, organelle, cellular and organism level contributing to alcohol-induced tissue injury/protection; (3) develop potential stress related biomarkers for prognosis, diagnosis of tissue injury/protection, furthermore identify new targets for their therapeutic interventions. Utilizing innovative experimental design and emerging technologies, such as deep sequencing, genomics, proteomics, metabolomics, bioinformatics, and novel imaging techniques these investigations are expected to provide a more comprehensive understanding of how alcohol affects the evolutionally conserved stress pathways and elucidate their roles in tissue injuries and repair. Opening Date: May 16, 2010. Application Due Dates: February 16, June 16, October 16 annually through May 2013.
Posted Date: March 17, 2010
Program Announcement (PA) Number: PA-10-094
————————————————————————————–
Stress Pathways in Alcohol Induced Organ Injury and Protection (R01) – This FOA issued by the National Institute on Alcohol Abuse and Alcoholism, NIH, encourages applications that propose studying the role of cellular stress responses, the cytoplasmic classical stress response or heat shock response (HSR) and the endoplasmic reticulum (ER) stress, in alcohol-induced tissue injury and tissue protection. While excessive alcohol use causes organ damage, moderate alcohol consumption may be beneficial. The underlying molecular mechanisms for this apparent dichotomy of alcohol’s harmful and salutary effects are currently not fully understood. Studies of the effects of alcohol on cellular stress pathways are critical to understand the mechanisms of alcohol-induced injuries or protection to develop new strategies for prevention, diagnosis and treatment. The purpose of this FOA is to: (1) acquire insight into how acute or chronic alcohol consumption affects cellular stress pathways and in turn, how these changes contribute to alcohol-induced injury/protection; (2) investigate how alcohol induced stress responses mediate cell survival and death signaling pathways at macromolecular, organelle, cellular and organism level contributing to alcohol-induced tissue injury/protection; (3) develop potential stress related biomarkers for prognosis, diagnosis of tissue injury/protection, furthermore identify new targets for their therapeutic interventions. Utilizing innovative experimental design and emerging technologies, such as deep sequencing, genomics, proteomics, metabolomics, bioinformatics, and novel imaging techniques these investigations are expected to provide a more comprehensive understanding of how alcohol affects the evolutionally conserved stress pathways and elucidate their roles in tissue injuries and repair. Opening Date: May 5, 2010. Application Due Dates: February 5, June 5, October 5 annually through May 2013.
Posted Date: March 17, 2010
Program Announcement (PA) Number: PA-10-093
————————————————————————————–
Alcohol Use Disorders: Treatment, Services Research, and Recovery (R01) – This FOA issued by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), NIH, encourages grant applications from institutions/organizations that propose to support research on behavioral and pharmacological treatment for alcohol use disorders; organizational, financial, and management factors that facilitate or inhibit the delivery of services for alcohol use disorders; and phenomenon of recovery from alcohol use disorders. Research objectives of this FOA include, but are not limited to, research within the following four broad research domains: (1) medications development for the treatment of alcohol use disorders and alcohol-induced tissue damage; (2) behavioral therapies and mechanisms of behavioral change; (3) health services research; and (4) recovery research. Cutting across these domains, NIAAA encourages treatment and health services-related studies on a number of special emphasis populations and topics including: (a) psychiatric/substance abuse/medical comorbidity, (b) adolescents, (c) fetal alcohol spectrum disorders, (d) health disparities/special populations, and (e) use of novel methods and technologies. This FOA will utilize the NIH Research Project Grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope: PA-10-102 that encourages applications under the R21 mechanism and PA-10-101 that encourages applications under the R03 mechanism. Eligibility: All. Opening Date: May 5, 2010. Application Due Dates: February 5, June 5, October 5 annually through May 2013.
Posted Date: March 17, 2010
Program Announcement (PA) Number: PA-10-100
————————————————————————————–
Alcohol Use Disorders: Treatment, Services Research, and Recovery (R21) – This FOA issued by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), NIH, encourages grant applications from institutions/organizations that propose to support research on behavioral and pharmacological treatment for alcohol use disorders; organizational, financial, and management factors that facilitate or inhibit the delivery of services for alcohol use disorders; and phenomenon of recovery from alcohol use disorders. Research objectives of this FOA include, but are not limited to, research within the following four broad research domains: (1) medications development for the treatment of alcohol use disorders and alcohol-induced tissue damage; (2) behavioral therapies and mechanisms of behavioral change; (3) health services research; and (4) recovery research. Cutting across these domains, NIAAA encourages treatment and health services-related studies on a number of special emphasis populations and topics including: (a) psychiatric/substance abuse/medical comorbidity, (b) adolescents, (c) fetal alcohol spectrum disorders, (d) health disparities/special populations, and (e) use of novel methods and technologies. This FOA will use the NIH Exploratory/Developmental (R21) award mechanism and runs in parallel with two FOAs of identical scientific scope: PA-10-100 that encourages applications under the R01 mechanism and PA-10-101 that encourages applications under the R03 mechanism. Eligibility: All. Opening Date: May 16, 2010. Application Due Dates: February 16, June 16, October 16 annually through May 2013.
Posted Date: March 17, 2010
Program Announcement (PA) Number: PA-10-102
————————————————————————————–
Alcohol Use Disorders: Treatment, Services Research, and Recovery (R03) – This FOA issued by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), NIH, encourages grant applications from institutions/organizations that propose to support research on behavioral and pharmacological treatment for alcohol use disorders; organizational, financial, and management factors that facilitate or inhibit the delivery of services for alcohol use disorders; and phenomenon of recovery from alcohol use disorders. Research objectives of this FOA include, but are not limited to, research within the following four broad research domains: (1) medications development for the treatment of alcohol use disorders and alcohol-induced tissue damage; (2) behavioral therapies and mechanisms of behavioral change; (3) health services research; and (4) recovery research. Cutting across these domains, NIAAA encourages treatment and health services-related studies on a number of special emphasis populations and topics including: (a) psychiatric/substance abuse/medical comorbidity, (b) adolescents, (c) fetal alcohol spectrum disorders, (d) health disparities/special populations, and (e) use of novel methods and technologies. This FOA will utilize the NIH Small Research Grant (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope: PA-10-100 that encourages applications under the R01 mechanism and PA-10-102 that encourages applications under the R21 mechanism. Eligibility: All. Opening Date: May 16, 2010. Application Due Dates: February 16, June 16, October 16 annually through May 2013.
Posted Date: March 17, 2010
Program Announcement (PA) Number: PA-10-101
————————————————————————————–
Targeted Clinical Trials To Reduce the Risk of Anti-microbial Resistance – The NIAID, NIH, supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Microbiology and Infectious Diseases has an interest in identifying innovative approaches to effectively treat bacterial infections with anti-microbials that minimize the development of drug resistance. This BAA targets infectious diseases where improved treatment strategies could reduce the risk of anti-microbial resistance and preserve the effectiveness of existing anti-microbials. A central goal of this solicitation is to target disease areas experiencing the greatest anti-microbial selective pressure, and within these areas, to develop strategies that test the safety and effectiveness of different therapeutic approaches/regimens to reduce the probability of the emergence of drug resistance by minimizing unnecessary drug exposure. Eligibility: All. This BAA will be available electronically on/about March 30, 2010.
Posted Date: March 16, 2010
Solicitation Number: BAA-DMID-NIHAI2010089
————————————————————————————–
Next Generation Genetic Association Studies (U01) – This FOA issued by the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health, encourages applications from institutions or organizations that propose to utilize cellular reprogramming, molecular profiling, and genomics to investigate functional aspects of genetic variation in humans. NHLBI is soliciting a phased technology development and implementation program whose goal is to add a functional dimension to genomic studies by combining cellular reprogramming strategies with molecular profiling or cellular assays, followed by integration of this information with existing genotypic and clinical phenotypic data to assess how naturally occurring human genetic variation influences the activities of biological networks in cell-based models of disease. Total Funding: $76M. Eligibility: All. LOI Due Date: May 17, 2010. Closing Date: June 15, 2010.
Posted Date: March 15, 2010
Funding Opportunity Number: RFA-HL-11-006
————————————————————————————–
Adherence Studies in Adolescents with Chronic Kidney or Urologic Diseases, or Diabetes (R01) – The purpose of the FOA is to support research to improve adherence in adolescents with chronic kidney or urologic diseases, or diabetes. Therefore, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications from new or established investigators to pursue research to better understand factors that influence adherence, develop appropriate measures of adherence, and test innovative strategies to enhance adherence in this vulnerable population. Adherence to a prescribed treatment regimen, including medications, devices and behavioral recommendations, can significantly impact morbidity and mortality for patients with chronic diseases, including chronic kidney or urologic disease and diabetes. When adherence to complex and seemingly rigid treatment regimens is poor, the results can be tragic. Adolescence can also be a particularly challenging time for adherence given the competing demands in an adolescent’s life, the unique developmental changes, and rapidly changing set of responsibilities as they transition to adulthood. There are few studies in pediatrics beyond the HIV literature that address non-adherence. Total Funding: $2M; Award Ceiling: $500K. Eligibility: All. Opening Date: October 15, 2010. LOI Due Date: October 18, 2010. Closing Date: November 15, 2010.
Posted Date: March 10, 2010
Funding Opportunity Number: RFA-DK-10-004
————————————————————————————–
Home and Family Based Approaches for the Prevention or Management of Overweight or Obesity in Early Childhood (R21) – This FOA issued by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung and Blood Institute (NHLBI), the Office of Behavioral and Social Sciences Research (OBSSR) and the Office of Disease Prevention (ODP), NIH, invites exploratory pilot/feasibility study and small clinical trial applications from institutions/organizations that propose to test novel home or family based interventions for the prevention or management of overweight in infancy and early childhood. Tested interventions can use behavioral (including dietary and physical activity), environmental, or other relevant approaches. Applications should focus on infants and young children (to age six years) and emphasize the role of home environment and the influence of family/extended family members and parents (including guardians/substantial care-providers) within the child’s home environment. The direct goal of this initiative is to fund research that will advance knowledge for innovative approaches to the prevention or management of overweight in children less than 6 years of age, with potential for future research clinical trial applications either in the home or linked to a community setting. Eligibility: All. Opening Date: May 16, 2010. LOI Due Date: May 16, 2010. Application Due Date: June 16, 2010.
Posted Date: March 9, 2010
Funding Opportunity Number: PA-10-128
————————————————————————————–
Epigenetic Factors Associated with Symptoms and Complications of Chronic Disorders (Competitive Revision R01) – The National Institute of Nursing Research (NINR) invites applications to stimulate research that addresses underlying epigenetic factors in symptom expression and complications resulting from chronic disorders. It is anticipated that the findings from this research will help 1) identify individuals at the highest risk for developing severe symptoms and complications secondary to chronic disorders, 2) maximize symptom management, and 3) reduce, prevent, or reverse the occurrence of complications. This FOA will utilize the Competitive Revision award mechanism and runs in parallel with a FOA of identical scientific scope, RFA-NR-10-004, that encourages applications under the R01 mechanism. Total Funding: $750K. Eligibility: All. Opening Date: April 17, 2010. LOI Due: April 17, 2010. Closing Date: May 17, 2010.
Posted Date: March 8, 2010
Funding Opportunity Number: RFA-NR-10-005
————————————————————————————–
Epigenetic Factors Associated with Symptoms and Complications of Chronic Disorders (R01) – The National Institute of Nursing Research (NINR) invites applications to stimulate research that addresses underlying epigenetic factors in symptom expression and complications resulting from chronic disorders. It is anticipated that the findings from this research will help 1) identify individuals at the highest risk for developing severe symptoms and complications secondary to chronic disorders, 2) maximize symptom management, and 3) reduce, prevent, or reverse the occurrence of complications. This FOA will utilize the R01 award mechanism and runs in parallel with a FOA of identical scientific scope, RFA-NR-10-005, that encourages applications under the Competitive Revision mechanism. Total Funding: $1.25M. Eligibility: All. Opening Date: April 17, 2010. LOI Due: April 17, 2010. Closing Date: May 17, 2010.
Posted Date: March 8, 2010
Funding Opportunity Number: RFA-NR-10-004
————————————————————————————–
Collaborative Clinical Trials in Drug Abuse (Collaborative R01) – This FOA seeks to support collaborative, multisite, clinical trials via combined R01 grant applications that all utilize a common clinical protocol with identical primary outcome(s). A large sample size is sometimes indicated in order to draw valid conclusions from clinical trials of substance-related disorders (SRDs), and is best achieved through multiple study sites. For some research questions, such as those studying an outcome in a specific patient population, a study site may be unable to recruit sufficient numbers of participants. In other circumstances, even where the main hypothesis can be addressed with the population available for study, certain hypotheses about sub-populations (based on gender, ethnicity, drug use patterns, comorbid conditions, etc.), interaction effects, or ancillary questions (e.g., such as about patient matching to treatment, unexpected outcomes, etc.) can only be examined by studying large cohorts of subjects. Eligibility: All. Opening Date: May 5, 2010. LOI Due: 30 days before submission. Due Dates: June 5, October 5, February 5 annually up to June 5, 2013.
Posted Date: March 8, 2010
Program Announcement (PA) Number: PAR-10-099
————————————————————————————–
Strategic Partnering to Evaluate Cancer Signatures [SPECS II] (U01) – This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI) of the National Institutes of Health (NIH), encourages the submission of grant applications for support of the clinical application of multi-analyte molecular signatures derived from comprehensive molecular annotation of tumors. The purpose of this initiative is to build on recent demonstrations that molecular signatures correlate with important clinical parameters in cancer. The goal of this initiative is also to create publications and data sets that will be available and accessible to the scientific community in order to further the development, design, and conduct of future clinical trials (e.g., incorporation of molecular signatures into future clinical trials and large clinical validation studies) and to encourage appropriate commercialization to benefit the public health. The NCI invites investigators to form strategic partnerships that will bring together the multi-disciplinary expertise and resources needed to determine how the information derived from comprehensive molecular analyses can be used to improve patient care and, ultimately, patient outcomes. Eligibility: All. LOI Due: May 15 annually thru 2012. Closing Date: June 15 annually thru 2012.
Posted Date: March 8, 2010
Funding Opportunity Number: PAR-10-126
————————————————————————————–
Collaborative Research for Molecular and Genomic Studies of Behavior in Animal Models (R01) – The National Institute of General Medical Sciences (NIGMS) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)invite submission of investigator-initiated research grant applications to support collaborative research, using molecular and/or genomic approaches to address questions about mechanisms of behavior in animal models. The purpose of the initiative is to facilitate collaborations between behavioral scientists and investigators with expertise in state-of-the-art molecular biology and/or genomics. NICHD is interested in research that addresses questions related to normal and abnormal development. NIGMS is interested in research that addresses questions related to non-developmental aspects of behavior, or to developmental aspects of behavior other than those that are of interest to NICHD. Eligibility: All. Opening Date: May 5, 2010. Due Dates: June 5, October 5, February 5 annually up to February 5, 2013.
Posted Date: March 8, 2010
Funding Opportunity Number: PA-10-125
————————————————————————————–
Recovery Act Limited Competition: The NIH Director’s ARRA Funded Pathfinder Award to Promote Diversity in the Scientific Workforce (DP4) – This NIH FOA invites applications for the NIH Director’s ARRA Pathfinder Award to Promote Diversity in the Scientific Workforce. The NIH recognizes a unique and compelling need to promote diversity in the biomedical, behavioral, clinical and social sciences research workforce. The NIH expects all of its efforts to diversify the workforce to lead to the recruitment of the most talented researchers from all groups; to improve the quality of the educational and training environment; to balance and broaden the perspective in setting research priorities; to improve the ability to recruit subjects from diverse backgrounds into clinical research protocols; and to improve the Nation’s capacity to address and eliminate health disparities. This new FOA introduces a new research grant program to encourage exceptionally creative individual scientists to develop highly innovative and possibly transforming approaches for promoting diversity within the biomedical research workforce. To be considered highly innovative, the proposed research must reflect ideas substantially different from those already being pursued or it must apply existing research designs in new and innovative ways to unambiguously identify factors that will improve the retention of students, postdocs and faculty from diverse backgrounds. Awardees must commit a major portion (generally 30% or more) of their research effort to activities supported by the Director’s Pathfinder Award and the proposed research must be endorsed by the highest levels of institutional management. Total Funding: $10M. Eligibility: All. Opening Date: April 4, 2010. LOI Due Date: April 5, 2010. Application Due Date: May 4, 2010.
Posted Date: March 5, 2010
Request for Applications (RFA) Number: RFA-OD-10-013
————————————————————————————–
NIAMS Accelerating Research Translation (ART) in Musculoskeletal and Skin Tissue Engineering and Regenerative Medicine Competitve Revision Award (R01) – The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) solicits ART applications in musculoskeletal and skin tissue engineering and regenerative medicine (TE/RM). The ART awards intend to offer revision support to active NIAMS R01, P01 and P50 (parent) grants for conducting large animal pre-clinical studies with the potential to immediately lead to human trials in musculoskeletal and skin TE/RM. These studies will 1) provide data required for Phase I/II human clinical trials in musculoskeletal and skin TE/RM, 2) demonstrate efficacy of a TE/RM therapy in musculoskeletal and skin TE/RM, or 3) develop pre-clinical large animal models that will have the potential to immediately lead TE/RM research into Phase I/II clinical trials. Early stage translational studies using small animals such as rodent and rabbit are not responsive to this FOA. Total Funding: $1M to make 1 to 3 ART awards for both RFA-AR-11-004 and RFA-AR-11-005. Eligibility: All. Opening Date: July 5, 2010. LOI Due Date: July 5, 2010. Application Due Date: August 4, 2010.
Posted Date: February 26, 2010
Request for Applications (RFA) Number: RFA-AR-11-004
————————————————————————————–
NIAMS Accelerating Research Translation (ART) in Musculoskeletal and Skin Tissue Engineering and Regenerative Medicine Competitive Revision Award (P01 and P50) – The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) solicits Accelerating Research Translation (ART) applications in musculoskeletal and skin tissue engineering and regenerative medicine (TE/RM). The ART awards intend to offer revision support (formerly referred to as a “competing supplement”) to active NIAMS R01, P01 and P50 (parent) grants for conducting large animal pre-clinical studies with the potential to immediately lead to human trials in musculoskeletal and skin TE/RM. These studies will 1) provide data required for Phase I/II human clinical trials in musculoskeletal and skin TE/RM, 2) demonstrate efficacy of a TE/RM therapy in musculoskeletal and skin TE/RM, or 3) develop pre-clinical large animal models that will have the potential to immediately lead TE/RM research into Phase I/II clinical trials. Early stage translational studies using small animals such as rodent and rabbit are not responsive to this FOA. Total Funding: $1M to make 1 to 3 ART awards for both RFA-AR-11-004 and RFA-AR-11-005. Eligibility: All. LOI Due Date: July 5, 2010. Application Due Date: August 4, 2010.
Posted Date: February 26, 2010
Request For Applications (RFA) Number: RFA-AR-11-005
————————————————————————————–
Centers for Advanced Diagnostics and Experimental Therapeutics in Lung Diseases Stage I (CADET I) (P50) – The purpose of this FOA issued by the NHLBI, National Institutes of Health, is to invite applications for clinical research centers for Centers for Advanced Diagnostics and Experimental Therapeutics in Lung Diseases Stage I (CADET I). The overall goal of the CADET program (Stages I and II) is to accelerate the development of novel agents for the diagnosis and treatment of lung diseases and sleep disordered breathing through the use of rational strategies based on fundamental pathobiologic processes. CADET I provides the opportunity to explore potential target(s) for validation to determine which are amenable for development of mechanism-based modalities for direct clinical application in the prevention, diagnosis, and treatment of pulmonary diseases and sleep disordered breathing. Companion FOAs for Clinical Research Centers (CRCs) and a Data Coordinating Center (DCC) for CADET Stage II (CADET II) will be released at a later date. Both the CRCs and DCC announcements will be open competitions. Centers that have been awarded in CADET I may apply for Clinical Research Centers in CADET II. LOI Due Date: April 12, 2010. Application Due Date: May 12, 2010.
Posted Date: February 26, 2010
Request For Applications (RFA) Number: RFA-HL-11-015
————————————————————————————–
Common Pathogenetic Mechanisms of Lung Cancer and COPD (R01) – This Funding Opportunity Announcement (FOA) issued by the National Heart, Lung, and Blood Institute and the National Cancer Institute, National Institutes of Health, solicits Research Project Grant (R01) applications from institutions/organizations to identify the fundamental etiopathogenetic commonalities between lung cancer and Chronic Obstructive Pulmonary Disease (COPD) in order to characterize: (a) the genotypic and phenotypic characteristics that determine individual susceptibility; and (b) the shared biochemical, molecular, and immunological pathways involved in the origin and progression of the two diseases. Total Funding: $24M. Number of Awards: 8. Eligibility: All. Opening Date: May 18, 2010. LOI Due Date: May 18, 2010. Application Due Date: June 18, 2010.
Posted Date: March 2, 2010
Request for Applications (RFA) Number: RFA-HL-11-002
————————————————————————————–
Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) – The Jointly Sponsored NIH Predoctoral Training Program in the Neurosciences supports broad and fundamental, early-stage graduate research training in the neurosciences via institutional NRSA research training grants (T32) at domestic institutions of higher education. The objective of the NRSA program is to provide predoctoral and postdoctoral research training opportunities for individuals interested in pursuing research careers in biomedical, behavioral and clinical research.
The purpose of the NRSA research training program is to help ensure that a diverse and highly trained workforce is available to assume leadership roles related to the Nation’s biomedical and behavioral research agenda.Trainees are supported during years 1 and 2 of their graduate research training when they are typically not committed to a dissertation laboratory. The primary objective is to prepare qualified individuals for careers in neuroscience that have a significant impact on the health-related research needs of the Nation. Eligibility: Universities and Colleges. Opening Date: April 25, 2010. LOI Due Date: April 25, 2010. Application Due Date: May 25, 2010.
Posted Date: March 2, 2010
Program Announcement (PA) Number: PAR-10-116
Mind’s Eye – DARPA is soliciting innovative research proposals in the area of machine-based visual intelligence. Proposed research should investigate innovative approaches that enable revolutionary advances in science, devices, or systems. Specifically excluded is research that primarily results in evolutionary improvements to the existing state of practice. The Mind’s Eye program seeks to develop in machines a capability that currently exists only in animals: visual intelligence. In particular, this program pursues the capability to learn generally applicable and generative representations of action between objects in a scene, directly from visual inputs, and then reason over those learned representations. A key distinction between this research and the state of the art in machine vision is that the latter has made continual progress in recognizing a wide range of objects and their properties—what might be thought of as the nouns in the description of a scene. The focus of Mind’s Eye is to add the perceptual and cognitive underpinnings for recognizing and reasoning about the verbs in those scenes, enabling a more complete narrative of action in the visual experience. Multiple awards are anticipated. The amount of resources made available under this BAA will depend on the quality of the proposals received and the availability of funds. Eligibility: All. Initial Closing: May 10, 2010; Final Closing: September 21, 2010.
Engineering Design of Advanced H2 – CO2 Membrane Separations – In this funding opportunity announcement (FOA), research will focus on hydrogen separations technology, including advanced separation membranes (inorganic, metallic and both materials), that provide high purity hydrogen and/or offer a combination of hydrogen separation with low-cost removal of (Carbon Dioxide) CO2 and other trace impurities from hydrogen-CO2 mixtures. The latter may involve improved membrane or adsorption systems that build upon and improve current separation efficiencies or development of new separation strategies. The primary purpose of this effort is to demonstrate the separation of hydrogen from coal (or coal-biomass) derived syngas via membranes at the pre-engineering/pilot scale. Applications are sought for research, development and demonstration (RD&D) at the pre-engineering/pilot scale for innovative membrane materials, concepts and strategies which separate hydrogen from a coal (coal-biomass)-based syngas with performance that is sufficient to meet the DOE 2015 targets of flux, selectivity, cost and chemical and mechanical robustness. Total Funding: $20M; Award Ceiling: $2M (Phase I), $10M (Phase II, III). Closing Date: May 17, 2010.
